Femasys stock.
Femasys stock price prediction is an act of determining the future value of Femasys shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Femasys' future price could yield a significant profit. Please, note that this module is not intended to be used solely to …Nov 27, 2023 · What is Femasys's consensus rating and price target? According to the issued ratings of 3 analysts in the last year, the consensus rating for Femasys stock is Buy based on the current 3 buy ratings for FEMY. The average twelve-month price prediction for Femasys is $9.00 with a high price target of $10.00 and a low price target of $7.00. What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has ...Femasys : Corporate Presentation June 2023. Disrupting Convention in Women's Health Through Continuous Innovation. This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not …
Femasys Inc. analyst ratings, historical stock prices, earnings estimates & actuals. FEMY updated stock price target summary.ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ...
Femasys expects the resulting patent, when issued, will have an anticipated expiration in 2039, at the earliest. In October, Femasys regained compliance with Nasdaq’s minimum bid price requirement, after having received a notice on June 1, 2023 from Nasdaq that they were not in compliance with such requirement.ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the …
Oct 24, 2023 · Femasys is a commercial-stage company with four approved products — FemaSeed (intratubal Insemination), FemVue (contrast generating device), FemCath (selective delivery catheter) and FemCerv ... Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. In depth view into FEMY (Femasys) stock including the latest price, news, dividend history, earnings information and financials.Operating Status Active. Last Funding Type Post-IPO Debt. Legal Name Femasys Inc. Stock Symbol NASDAQ:FEMY. Company Type For Profit. Contact Email [email protected]. Phone Number 1 (770) 500-3910. Femasys is a biomedical company focused on transforming women’s healthcare worldwide by …See the company profile for Femasys Inc. (FEMY) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...
ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a suite of product candidates and products that include minimally invasive, in-office technologies for reproductive health, announced that the United States Patent and …
Femasys Inc. is a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally ...
Oct 3, 2023 · Femasys Inc. FEMY shares are trading lower Tuesday. The stock has been volatile since the company received FDA 510(k) clearance for FemaSeed, an infertility treatment, towards the end of September . Wall Street’s analysts know that buying low is part of a winning stock strategy, and they’ve been looking for stocks that are low – undervalued, and possibly hitting bottom. It’s the first step in an old formula for success, with the next, of course, being to sell high. Some recent picks from the analyst corps, pulled up via the TipRanks platform, may raise …According to 3 stock analysts, the average 12-month stock price forecast for Femasys stock is $9.00, which predicts an increase of 845.18%. The lowest target is $7.00 and the highest is $10. On average, analysts rate Femasys stock as a strong buy.Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA. Stock split history for Femasys since 2021.That’s a massive surge in trading volume compared to Femasys’ daily average of about 3.3 million shares. FEMY stock is up 180.9% as of Tuesday morning after closing out Monday down 63.2% year ...Nov 28, 2023 · What is the target price for Femasys (FEMY) stock? The latest price target for Femasys ( NASDAQ: FEMY) was reported by HC Wainwright & Co. on Tuesday, November 14, 2023. The analyst firm set a ...
On the revenue front, Femasys achieved $320.51 thousand in sales, ... FEMY stock showed interesting movements on August 10, 2023. FEMY’s previous close was $0.50, and the stock opened at the same price. Throughout the day, the stock’s range fluctuated between $0.34 and $0.50.Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.Nov 29, 2023 · Femasys GAAP EPS of -$0.22 misses by $0.02, revenue of $0.32M misses by $0.05M SA News Thu, Aug. 10 Femsys stock jumps 21% after FDA green lights FemBloc testing Comparatively, 16.4% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Earnings & Valuation. This table compares Beyond Air and Femasys’ revenue, earnings per share …Portfolio Overview. Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs. Femasys has an expansive, internally-created intellectual property ... Aug 10, 2023 · Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update. August 10, 2023 08:00 ET ... Common stock, $.001 par, 200,000,000 authorized, ...
Femasys, a medical device company, is set to launch its minimally invasive reproductive health products for women in 2024. ... Its stock ran from $0.33 to an intraday high of $4.75 a few days ...
Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.Femasys Inc (FEMY) has experienced a 3.06% rise in stock performance for the past week, with a -36.36% drop in the past month, and a 113.56% rise in the past quarter. The volatility ratio for the week is 11.20%, and the volatility levels for the past 30 days are at 13.36% for FEMY.Oct 2, 2023 · What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has ... Femasys Inc. (FEMY) delivered earnings and revenue surprises of -8.70% and 13.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Oct 2, 2023 · Femasys Inc, a medical technology company, has been attracting attention from investors due to its positive stock performance on October 2, 2023. According to data from CNN Money, the company has received favorable price forecasts from four analysts, with a median target of $8.50. The high estimate is $13.00, while the low estimate is $5.00. NASDAQ:FEMY - Femasys Stock Price, News & Analysis Femasys Stock Price, News & Analysis (NASDAQ:FEMY) $0.98 -0.03 (-2.98%) (As of 11/29/2023 ET) …WebFemasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.55.59%. Dividend Yield. 3.98%. Kenvue's products fall into three segments: self care like Tylenol pain reliever, skin health and beauty such as Neutrogena lotions, and essential health like Band ...11 oct 2023 ... ... Stock Market LLC (Nasdaq) informing Femasys that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule ...
Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...
Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.
Get the latest Femasys Inc. (FEMY) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Nov. 30, 2023 5:40 PM ET Femasys Inc. (FEMY) By: Tiyashi Datta, SA News Editor. Femasys ( NASDAQ: FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an ...Femasys Inc FEMY shares surged after the company received FDA 510 (k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube. Infertility has affected an increasing number of women – estimated at 10 million in the U.S., according to the Center for Disease Control.FEMY Earnings Date and Information. Femasys has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 4th, 2024 based off prior year's report dates. Read More.Portfolio Overview. Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs. Femasys has an expansive, internally-created intellectual property ...In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions.Publish : 04 Oct 2023, 07:17 PM Update : 04 Oct 2023, 07:17 PM. Femasys (NASDAQ: FEMY) stock is down 50% over night from highs. A reasonable bet would be that FEMY stock will continue to fall back to more reasonable levels. For, as far as we can see at least, this is a flurry of speculation producing far too much movement for the objective ...ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the …- FemaSeed ® is the first-ever, first-line approach designed to deliver sperm directly where conception occurs -. ATLANTA, April 18, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in …Femasys Inc. FEMY shares are trading lower Tuesday. The stock has been volatile since the company received FDA 510 (k) clearance for FemaSeed, an infertility treatment, towards the end of September. What To Know: On Sept. 26, shares of the stock surged on news of the FDA clearance for FemaSeed, although the stock pulled back the …Get the latest Femasys Inc. (FEMY) stock news and headlines to help you in your trading and investing decisions.Web
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch - Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - …WebIn a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions.Femasys (NASDAQ: FEMY) stock is heading more than 17% higher on Monday morning. Better Choice (NYSEMKT: BTTR) shares are getting an over 15% boost this morning.Instagram:https://instagram. graphite companies stockhow to set up a real estate investment fundwall street journal delivery problemshow do i invest in a startup company ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include ... how to buy chinese stocksbiggest gainers premarket Femasys Inc. Common Stock (FEMY) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time After-Hours Live Key Data Bid Price and Ask Price The bid & ask refers to the …Web best penny stocks on cash app On average, Wall Street analysts predict. that Femasys's share price could reach $9.00 by Nov 14, 2024. The average Femasys stock price prediction forecasts a potential upside of 821.19% from the current FEMY share price of $0.98.Femasys Inc FEMY shares surged after the company received FDA 510 (k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube. Infertility has affected an increasing number of women – estimated at 10 million in the U.S., according to the Center for Disease Control.https://www.femasys.com. Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine ...